TY - JOUR
T1 - Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells
AU - Martín-Rufián, Mercedes
AU - Nascimento-Gomes, Renata
AU - Higuero, Ana
AU - Crisma, Amanda R.
AU - Campos-Sandoval, José A.
AU - Gómez-García, María C.
AU - Cardona, Carolina
AU - Cheng, Tzuling
AU - Lobo, Carolina
AU - Segura, Juan A.
AU - Alonso, Francisco J.
AU - Szeliga, Monika
AU - Albrecht, Jan
AU - Curi, Rui
AU - Márquez, Javier
AU - Colquhoun, Alison
AU - Deberardinis, Ralph J.
AU - Matés, José M.
N1 - Funding Information:
Acknowledgements We apologize for omissions of original references because of space limitations. Thanks are due to Rosa M. Moreno and Juan I. Rodríguez-Arranz for their valuable help in experimental tasks. This work was supported by Ministerio de Educación of Spain, PHB2010-0014-PC; Ministerio de Ciencia y Tecnología of Spain, SAF2010-17573; Junta de Andalucía, CVI-6656, Spain; PI-0825-2010, Junta de Andalucía, Spain; grant RD06/1012 of the RTA RETICS network from the Spanish Health Institute Carlos III, Spain. R.J.D. is supported by grants from the NIH (R01 CA157996), the Cancer Prevention and Research Institute of Texas (HIRP100437 and RP101243), the Robert A. Welch Foundation (I-1733), and the Damon-Runyon Cancer Research Foundation. M.S. and J.A. received support from the Ministry of Science and Higher Education (National Science Centre), grant NN401 039238. Thanks are also due to CAPES/DGU 250/11, Brazil.
PY - 2014/3
Y1 - 2014/3
N2 - Mitochondrial glutaminase (GA) plays an essential role in cancer cell metabolism, contributing to biosynthesis, bioenergetics, and redox balance. Humans contain several GA isozymes encoded by the GLS and GLS2 genes, but the specific roles of each in cancer metabolism are still unclear. In this study, glioma SFxL and LN229 cells with silenced isoenzyme glutaminase KGA (encoded by GLS) showed lower survival ratios and a reduced GSH-dependent antioxidant capacity. These GLS-silenced cells also demonstrated induction of apoptosis indicated by enhanced annexin V binding capacity and caspase 3 activity. GLS silencing was associated with decreased mitochondrial membrane potential (ΔΨm) (JC-1 dye test), indicating that apoptosis was mediated by mitochondrial dysfunction. Similar observations were made in T98 glioma cells overexpressing glutaminase isoenzyme GAB, encoded by GLS2, though some characteristics (GSH/GSSG ratio) were different in the differently treated cell lines. Thus, control of GA isoenzyme expression may prove to be a key tool to alter both metabolic and oxidative stress in cancer therapy. Interestingly, reactive oxygen species (ROS) generation by treatment with oxidizing agents: arsenic trioxide or hydrogen peroxide, synergizes with either KGA silencing or GAB overexpression to suppress malignant properties of glioma cells, including the reduction of cellular motility. Of note, negative modulation of GLS isoforms or GAB overexpression evoked lower c-myc and bcl-2 expression, as well as higher pro-apoptotic bid expression. Combination of modulation of GA expression and treatment with oxidizing agents may become a therapeutic strategy for intractable cancers and provides a multi-angle evaluation system for anti-glioma pre-clinical investigations. Key message: Silencing GLS or overexpressing GLS2 induces growth inhibition in glioma cell lines. Inhibition is synergistically enhanced after arsenic trioxide (ATO) or H2O2 treatment. Glutatione levels decrease in GLS-silenced cells but augment if GLS2 is overexpressed. ROS synergistically inhibit cell migration by GLS silencing or GLS2 overexpression. c-myc, bid, and bcl-2 mediate apoptosis resulting from GLS silencing or GLS2 overexpression.
AB - Mitochondrial glutaminase (GA) plays an essential role in cancer cell metabolism, contributing to biosynthesis, bioenergetics, and redox balance. Humans contain several GA isozymes encoded by the GLS and GLS2 genes, but the specific roles of each in cancer metabolism are still unclear. In this study, glioma SFxL and LN229 cells with silenced isoenzyme glutaminase KGA (encoded by GLS) showed lower survival ratios and a reduced GSH-dependent antioxidant capacity. These GLS-silenced cells also demonstrated induction of apoptosis indicated by enhanced annexin V binding capacity and caspase 3 activity. GLS silencing was associated with decreased mitochondrial membrane potential (ΔΨm) (JC-1 dye test), indicating that apoptosis was mediated by mitochondrial dysfunction. Similar observations were made in T98 glioma cells overexpressing glutaminase isoenzyme GAB, encoded by GLS2, though some characteristics (GSH/GSSG ratio) were different in the differently treated cell lines. Thus, control of GA isoenzyme expression may prove to be a key tool to alter both metabolic and oxidative stress in cancer therapy. Interestingly, reactive oxygen species (ROS) generation by treatment with oxidizing agents: arsenic trioxide or hydrogen peroxide, synergizes with either KGA silencing or GAB overexpression to suppress malignant properties of glioma cells, including the reduction of cellular motility. Of note, negative modulation of GLS isoforms or GAB overexpression evoked lower c-myc and bcl-2 expression, as well as higher pro-apoptotic bid expression. Combination of modulation of GA expression and treatment with oxidizing agents may become a therapeutic strategy for intractable cancers and provides a multi-angle evaluation system for anti-glioma pre-clinical investigations. Key message: Silencing GLS or overexpressing GLS2 induces growth inhibition in glioma cell lines. Inhibition is synergistically enhanced after arsenic trioxide (ATO) or H2O2 treatment. Glutatione levels decrease in GLS-silenced cells but augment if GLS2 is overexpressed. ROS synergistically inhibit cell migration by GLS silencing or GLS2 overexpression. c-myc, bid, and bcl-2 mediate apoptosis resulting from GLS silencing or GLS2 overexpression.
KW - Apoptosis
KW - Cancer
KW - Glioma
KW - Glutaminase
KW - Glutathione
KW - ROS
UR - http://www.scopus.com/inward/record.url?scp=84898477213&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898477213&partnerID=8YFLogxK
U2 - 10.1007/s00109-013-1105-2
DO - 10.1007/s00109-013-1105-2
M3 - Article
C2 - 24276018
AN - SCOPUS:84898477213
SN - 0946-2716
VL - 92
SP - 277
EP - 290
JO - Clinical Investigator
JF - Clinical Investigator
IS - 3
ER -